Takeda, Ultragenyx deal

Ultragenyx and Takeda partnered to develop and commercialize therapies to treat rare genetic diseases. Ultragenyx will receive an exclusive license to an undisclosed preclinical Takeda candidate in a pre-determined “field of use” and an exclusive option to co-develop and co-commercialize the candidate in additional therapeutic areas.

Ultragenyx may also opt to obtain worldwide rights to up to five additional Takeda candidates for rare diseases under a five-year research collaboration between the companies. Takeda will receive an exclusive option to commercialize any of the candidates in Asia and an option to obtain exclusive rights to one other Ultragenyx candidate in Japan. ...